{"id":"active-jnj-drug","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4802039","moleculeType":"Unknown","molecularWeight":"358.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action is not well understood, but it is believed to work by binding to a specific receptor and inhibiting its activity.","oneSentence":"Active JNJ drug is a monoclonal antibody that targets a specific molecular target.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:18:57.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT02230384","phase":"PHASE2","title":"Novel Smoking Cessation Drug for Schizophrenia","status":"COMPLETED","sponsor":"K.N. Roy Chengappa","startDate":"2014-09","conditions":"Smoking Cessation","enrollment":62},{"nctId":"NCT01959282","phase":"PHASE2","title":"A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-11-15","conditions":"Colitis, Ulcerative","enrollment":219},{"nctId":"NCT02217527","phase":"PHASE2","title":"Test of Novel Drug for Smoking Cessation","status":"COMPLETED","sponsor":"Chengappa, K.N. Roy, MD","startDate":"2014-11","conditions":"Smoking Cessation","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":422,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-39393406"],"phase":"phase_2","status":"active","brandName":"Active JNJ Drug","genericName":"Active JNJ Drug","companyName":"Chengappa, K.N. Roy, MD","companyId":"chengappa-k-n-roy-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Active JNJ drug is a monoclonal antibody that targets a specific molecular target. Used for Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}